Shares of Health Care sector company DexCom moved -2.2% today, and are now trading at a price of $95.3. The large-cap stock's daily volume was 1,246,826 compared to its average volume of 5,086,295. The S&P 500 index returned a 0.0% performance.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company is based in San Diego and has 7,500 full time employees. Its market capitalization is $36,819,509,248.
20 analysts are following DexCom and have set target prices ranging from $98.0 to $160.0 per share. On average, they have given the company a rating of buy. At today's prices, DXCM is trading -29.8% away from its average analyst target price of $135.75 per share.
Over the last year, DXCM shares have gone down by -17.0%, which represents a difference of -32.0% when compared to the S&P 500. The stock's 52 week high is $139.55 per share and its 52 week low is $74.75. With average free cash flows of $215.2 Million that have been growing at an average rate of 42.3% over the last 6 years, DexCom declining stock performance may not be reflective of the quality of its underlying business.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 771,400 | 305,400 | 466,000 | 52.94 |
| 2022 | 669,500 | 364,800 | 304,700 | 471.67 |
| 2021 | 442,500 | 389,200 | 53,300 | -80.73 |
| 2020 | 475,600 | 199,000 | 276,600 | 105.65 |
| 2019 | 314,500 | 180,000 | 134,500 | 139.75 |
| 2018 | 123,200 | 67,100 | 56,100 |
